A case of Castleman disease that improved after kidney transplantation

Lee, Hee Ryong; An, Jung Myung; Lee, Dong Ryeol; Choi, Hyun Wook; Oh, Joon Seok; Kim, Joong Kyung

doi:10.4285/jkstn.2019.33.1.13

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 A case involving a 56-year-old man with CD who improved after kidney transplantation was recently reported. 17 Corticosteroids inhibit inflammation and reduce lymphocyte proliferation. Thus, these drugs are an option for relieving symptoms during acute exacerbations of idiopathic multicentric CD; however, most patients relapse when the steroid dose is gradually decreased.…”

Section: Discussionmentioning

confidence: 99%

Multicentric Castleman’s disease in a renal allograft recipient: a case report and literature review

et al. 2020

View full text Add to dashboard Cite

Giant lymph node hyperplasia is the main symptom of Castleman's disease (CD), which is a rare and easily overlooked lymphoproliferative disease that mimics both benign and malignant lesions. Several cases of CD after renal transplantation have been reported in the literature. A 43-yearold man was admitted to our medical center with high serum globulin levels after receiving a living donor kidney transplant. A lymph node biopsy raised suspicion for multicentric CD. Because of the poor therapeutic effect of reduction of immunosuppression, the patient was treated with CHOP chemotherapy comprising four cycles of monthly cyclophosphamide (750 g/m 2 , day 1), vincristine (1.4 g/m 2 , day 1), doxorubicin (50 g/m 2 , day 1), and prednisone (60 mg/m 2 , daily). Following the treatment, his serum globulin levels decreased to the normal range. At the 2-year follow-up examination, the abdominal, axillary, and inguinal lymph nodes had significantly decreased in size. Without a pathological diagnosis, multicentric CD after renal transplantation can be easily ignored and misdiagnosed. If the clinical signs cannot be relieved by minimizing the dose of common immunosuppressants, the CHOP regimen may be a better option. Biological agents may be added in patients with positive immunohistochemistry staining and good economic conditions.

show abstract

Section: Discussionmentioning

confidence: 99%